Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, age 18 to 65 years~  * Subjects with Severe hemophilia A with a documented plasma FVIII level of \<1%~ * ≥ 150 exposure days with FVIII concentrate(s) as supported by medical records~Exclusion Criteria:~* Evidence of current or past inhibitor antibody~  * History of any congenital or acquired coagulation disorders other than hemophilia A~ * Platelet count \<75,000/mm3~ * Abnormal renal function (serum creatinine \>2 times the upper limit of the normal \[ULN\] range)~ * Active liver disease verified by medical history or persistently elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5 times the ULN or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio (INR) \>1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAY81-8973 (Type: EXPERIMENTAL): BAY81-8973 infusion to analyze pharmacokinetics
- Advate (Type: OTHER): Advate infusion to analyze pharmacokinetics.

Based on this trial design, predict the completion outcome and termination type (if applicable).